ACOG releases statement on 17p hydroxyprogesterone caproate

  • American College of Obstetricians and Gynecologists

  • Elisabeth Aron, MD, MPH, FACOG
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • After PROLONG trial results, the American College of Obstetricians and Gynecologists (ACOG) continues to endorse the use of weekly 17-hydroxyprogesterone caproate (17p) to reduce risk for spontaneous preterm birth.

Why this matters

  • Preterm birth is a major cause of neonatal morbidity and mortality.
  • The PROLONG trial demonstrated no difference in preterm birth composite index in women with weekly 17p vs placebo.

Key points

  • Current ACOG guidelines will remain in effect.
  • Additional planned meta-analyses and secondary analyses are needed to assess the effects of the intervention.

Study design

  • ACOG reviews the results and implications of the PROLONG clinical trial, a randomized, double-blind clinical trial evaluating 17p injection (250 mg/mL) and its effects in reducing preterm birth and neonatal morbidity/mortality in patients with a history of a prior spontaneous singleton preterm delivery.
  • Funding: None disclosed.

Limitations

  • ACOG will continue to monitor this topic, and recommendations may change with future research.